Form 8-K - Current report:
SEC Accession No. 0001493152-24-048316
Filing Date
2024-12-02
Accepted
2024-12-02 17:16:24
Documents
15
Period of Report
2024-11-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 49525
2 ex99-1.htm EX-99.1 17346
3 ex99-1_001.jpg GRAPHIC 4774
  Complete submission text file 0001493152-24-048316.txt   262145

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ser-20241126.xsd EX-101.SCH 3042
5 XBRL LABEL FILE ser-20241126_lab.xml EX-101.LAB 34916
6 XBRL PRESENTATION FILE ser-20241126_pre.xml EX-101.PRE 24614
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3966
Mailing Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806
Business Address 601 GENOME WAY SUITE 2001 HUNTSVILLE AL 35806 (256) 327-9630
Serina Therapeutics, Inc. (Filer) CIK: 0001708599 (see all company filings)

EIN.: 821436829 | State of Incorp.: AL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38519 | Film No.: 241520111
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)